Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “LPCN 1021 is gelatin capsule product provided as 112.5 mg testosterone undecanoate per capsule.”In the company’s words, NCT03868059 on ClinicalTrials.gov
- Tested for
- Hypogonadism, Male
- Main trialPhase 3
- “This is an open-label, multi-center, single arm study evaluating the blood pressure (BP) changes from baseline (Visit 3) to post-treatment (Visit 5) assessed by ambulatory blood pressure monitoring (ABPM) in LPCN 1021 treated adult hypogonadal male subjects.”In the company’s words, NCT03868059 on ClinicalTrials.gov
- Other names
- TLANDO
Other drugs for Hypogonadism, Male
- Testosterone cypionateAmneal Pharmaceuticals, LLC · Phase 3
- XYOSTEDHalozyme Therapeutics · Phase 3
- Testosterone Cypionate InjectionAzurity Pharmaceuticals · Marketed (Phase 4 trial)
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 19 Feb 2019 | Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026